{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:28:47Z","timestamp":1791224927600,"version":"4.1.0"},"reference-count":60,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.22721","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T15:34:16Z","timestamp":1658158456000},"page":"e2222721","source":"Crossref","is-referenced-by-count":30,"title":["Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma"],"prefix":"10.1001","volume":"5","author":[{"given":"Christopher D.","family":"Griffiths","sequence":"first","affiliation":[{"name":"Department of Surgery, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasia","family":"Tywonek","sequence":"additional","affiliation":[{"name":"Department of Surgery, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon M.","family":"Meyers","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo E.","family":"Serrano","sequence":"additional","affiliation":[{"name":"Department of Surgery, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Division of General Surgery, Juravinski Hospital, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"issue":"3","key":"zoi220644r1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.v71.3","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"zoi220644r2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx030","article-title":"Annual report to the nation on the status of cancer, 1975-2014, featuring survival.","volume":"109","author":"Jemal","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"zoi220644r3","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma.","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi220644r4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines.","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann Oncol"},{"issue":"36","key":"zoi220644r5","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/JCO.20.02672","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline.","volume":"38","author":"Gordan","year":"2020","journal-title":"J Clin Oncol"},{"key":"zoi220644r6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.652172","article-title":"Lessons from immune checkpoint inhibitor trials in hepatocellular carcinoma.","volume":"12","author":"Mohr","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"zoi220644r7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi220644r8","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"10126","key":"zoi220644r9","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"10064","key":"zoi220644r10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"zoi220644r11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma.","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi220644r12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial.","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"issue":"20","key":"zoi220644r13","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi220644r14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial.","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi220644r15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","article-title":"Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.","volume":"72","author":"Cheng","year":"2020","journal-title":"J Hepatol"},{"key":"zoi220644r16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review.","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"zoi220644r18","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"9","key":"zoi220644r20","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (MINORS): development and validation of a new instrument.","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"zoi220644r21","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"zoi220644r22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. introduction-GRADE evidence profiles and summary of findings tables.","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"zoi220644r23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.","volume":"33","author":"Cainap","year":"2015","journal-title":"J Clin Oncol"},{"issue":"32","key":"zoi220644r24","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.","volume":"31","author":"Cheng","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi220644r25","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1200\/jco.2015.33.3_suppl.339","article-title":"Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): a randomized phase II trial.","volume":"33","author":"Cheng","year":"2015","journal-title":"JCO"},{"issue":"4","key":"zoi220644r26","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2015.06.001","article-title":"Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: a phase 2 randomized study.","volume":"63","author":"Cheng","year":"2015","journal-title":"J Hepatol"},{"issue":"3","key":"zoi220644r27","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/hep.v64.3","article-title":"Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.","volume":"64","author":"Cheng","year":"2016","journal-title":"Hepatology"},{"issue":"26","key":"zoi220644r28","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma.","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"28","key":"zoi220644r29","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.","volume":"31","author":"Johnson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi220644r30","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1093\/annonc\/mdv388","article-title":"Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.","volume":"26","author":"Kang","year":"2015","journal-title":"Ann Oncol"},{"issue":"15","key":"zoi220644r31","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1200\/JCO.2020.38.15_suppl.4599","article-title":"Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.","volume":"38","author":"Kaseb","year":"2020","journal-title":"JCO"},{"issue":"27","key":"zoi220644r32","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study.","volume":"39","author":"Kelley","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi220644r33","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/annonc\/mdw054","article-title":"Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77\/08 and SASL 29).","volume":"27","author":"Koeberle","year":"2016","journal-title":"Ann Oncol"},{"issue":"14","key":"zoi220644r34","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.ejca.2011.05.007","article-title":"Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.","volume":"47","author":"Kudo","year":"2011","journal-title":"Eur J Cancer"},{"key":"zoi220644r35","doi-asserted-by":"publisher","first-page":"v875","DOI":"10.1093\/annonc\/mdz394.030","article-title":"Randomised efficacy and safety results for atezolizumab (atezo) + bevacizumab (bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC).","volume":"30","author":"Lee","year":"2019","journal-title":"Ann Oncol"},{"issue":"28","key":"zoi220644r36","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","article-title":"Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.","volume":"31","author":"Llovet","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi220644r37","doi-asserted-by":"publisher","first-page":"P219","DOI":"10.1016\/S2468-1253(21)00385-X","article-title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.","volume":"7","author":"Marron","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"zoi220644r38","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/s41416-018-0051-8","article-title":"A multicentre, open-label, phase-I\/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs sorafenib in European patients with advanced hepatocellular carcinoma.","volume":"118","author":"Palmer","year":"2018","journal-title":"Br J Cancer"},{"issue":"5","key":"zoi220644r39","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(18)30146-3","article-title":"Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.","volume":"19","author":"Rimassa","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi220644r40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(12)70490-4","article-title":"Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.","volume":"14","author":"Santoro","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi220644r41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jama.2014.7189","article-title":"Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.","volume":"312","author":"Zhu","year":"2014","journal-title":"JAMA"},{"issue":"7","key":"zoi220644r42","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi220644r43","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.2013.53.7746","article-title":"SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.","volume":"33","author":"Zhu","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi220644r44","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased a-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"issue":"28","key":"zoi220644r45","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.3748\/wjg.v25.i28.3704","article-title":"Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.","volume":"25","author":"Akateh","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"4","key":"zoi220644r46","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s12029-020-00497-7","article-title":"Why adjuvant and neoadjuvant therapy failed in HCC: can the new immunotherapy be expected to be better?","volume":"51","author":"Dikilitas","year":"2020","journal-title":"J Gastrointest Cancer"},{"issue":"34","key":"zoi220644r47","doi-asserted-by":"publisher","first-page":"36838","DOI":"10.18632\/oncotarget.v6i34","article-title":"Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis.","volume":"6","author":"Qi","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"zoi220644r48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/hep.29485","article-title":"Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis.","volume":"67","author":"Kulik","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"zoi220644r49","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/S1470-2045(11)70175-9","article-title":"Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.","volume":"13","author":"Clavien","year":"2012","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi220644r50","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s11901-019-00492-y","article-title":"Downstaging and expanded criteria hepatocellular carcinoma liver transplantation.","volume":"18","author":"Abreu","year":"2019","journal-title":"Curr Hepatol Rep"},{"issue":"12","key":"zoi220644r51","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.hpb.2018.06.1798","article-title":"Preoperative strategies to improve resectability for hepatocellular carcinoma: a systematic review and meta-analysis.","volume":"20","author":"Tustumi","year":"2018","journal-title":"HPB (Oxford)"},{"issue":"6","key":"zoi220644r52","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00268-016-3421-5","article-title":"Anatomical resection but not surgical margin width influence survival following resection for HCC: a propensity score analysis.","volume":"40","author":"Lee","year":"2016","journal-title":"World J Surg"},{"issue":"6","key":"zoi220644r53","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3892\/ijo","article-title":"Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma.","volume":"14","author":"Suzuki","year":"1999","journal-title":"Int J Oncol"},{"issue":"3","key":"zoi220644r54","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/ajt.v20.3","article-title":"Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?","volume":"20","author":"Nordness","year":"2020","journal-title":"Am J Transplant"},{"issue":"5","key":"zoi220644r55","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1111\/ajt.v21.5","article-title":"PD-1 inhibitor as bridge therapy to liver transplantation?","volume":"21","author":"Tabrizian","year":"2021","journal-title":"Am J Transplant"},{"issue":"10","key":"zoi220644r56","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/tri.2011.24.issue-10","article-title":"Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.","volume":"24","author":"Truesdale","year":"2011","journal-title":"Transpl Int"},{"key":"zoi220644r57","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12885-015-1373-z","article-title":"Impact of neo-adjuvant sorafenib treatment on liver transplantation in HCC patients\u2014a prospective, randomized, double-blind, phase III trial.","volume":"15","author":"Hoffmann","year":"2015","journal-title":"BMC Cancer"},{"key":"zoi220644r19","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5","author":"Health","year":"2017"},{"key":"zoi220644r17","unstructured":"Higgins? JPT, Thomas? J, Chandler? J, . Cochrane Handbook for Systematic Reviews of Interventions version 6.2. Accessed June 10, 2022. https:\/\/training.cochrane.org\/handbook"},{"key":"zoi220644r58","unstructured":"Fan? J. A study to evaluate efficacy and safety of hepatic resection for liver cancer with PVTT, HVTT or IVCTT after initial ate\/bev. ClinicalTrials.gov. Updated March 3, 2022. Accessed June 10, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04649489"},{"key":"zoi220644r59","unstructured":"Franses? J. SBRT + atezolizumab + bevacizumab in resectable HCC. ClinicalTrials.gov. Updated February 11, 2022. Accessed June 10, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04857684"},{"key":"zoi220644r60","unstructured":"MD Anderson Cancer Center. Atezolizumab and bevacizumab before surgery for the treatment of resectable liver cancer. ClinicalTrials.gov. Updated February 22, 2022. Accessed June 10, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04721132"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2794295\/griffiths_2022_oi_220644_1657298989.04563.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T15:34:21Z","timestamp":1658158461000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2794295"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.22721","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]}}}